All articles by GlobalData Healthcare

SLE and LN market expected to reach $5.9bn across 7MM by 2034

A notable growth in the systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM;…
Significant opportunities exist in the global pain market for novel mechanisms and modalities

Pain is a multifaceted, highly heterogeneous disorder that is treated using analgesics. There is a lack of diversity within the…
AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals

Under the three-year deal, AbbVie agreed to lower prices on certain Medicaid drugs and expand distribution through the TrumpRx direct-to-patient…
The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears

This year, sales of Bristol Myers Squibb’s (BMS) and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% due…
UK–US zero‑tariff deal pricing reforms position UK as global hub for new medicines

The key element of the agreement is confirmation that UK pharmaceutical exports to the US will face a preferential tariff…

JPM26: Immunocore Signals Entry into type 1 diabetes

At the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on 14th January 2026, Immunocore outlined 2026 strategic priorities…
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens

At the 44th Annual J.P. Morgan Healthcare Conference, Atea Pharmaceuticals outlined its strategy for hepatitis C virus (HCV), showcasing its…
JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As

The J.P. Morgan Healthcare Conference held in San Francisco, California from 12 January to 15 January 2026 saw a key…
JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency

Humira (adalimumab), AbbVie’s monoclonal antibody treatment, was first launched in 2002 for rheumatoid arthritis and since expanded to additional indications…
JPM26: Matrix-M Technology is central to Novavax’s strategy

At the J. P. Morgan Healthcare Conference 2026, Novavax’s President and CEO, John C. Jacobs, reviewed the company’s successes in…